source
- Merck, Gilead report mixed outcomes in key lung cancer, HIV studiesTrodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
- Roche commits $700 million to co-develop Nurix's BTK-degrading drug bexobrutidegRoche announced a partnership with Nurix Therapeutics to co-develop a protein-degrading therapy called bexobrutideg, which targets the BTK enzyme. Under the agreement, Roche will pay $700 million…